MiNA Therapeutics Presents New Pre-Clinical Data from Sickle Cell Disease Program at the European Hematology Association 2025 Congress

Contributed by: Business Wire

Logo

Tags

Science

Biotechnology

Research

Pharmaceutical

General Health

Health

Health Technology

Genetics

MTL-HBG

More Like This

MiNA Therapeutics Presents New Data for its HbF Program at the Keystone Symposia’s Delivery of Nucleic Acid Therapeutics Conference

BeiGene Showcases Strength of Hematology Portfolio at EHA 2025 with New Data Highlighting BRUKINSA’s Leadership and Next-Generation Innovation

e-therapeutics to Present Preclinical Data on ETX-148 at EAHAD 2025

PR Newswire associated0

BIAL Announces Oral Presentation at GBA1 Meeting 2025

BeiGene Highlights New Hematology Portfolio and Pipeline Data at EHA2024

Sangamo Therapeutics to Present Neurology-Focused Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

Incyte Announces Multiple Presentations, Including New Late-Breaking Data for its mutCALR-Directed Monoclonal Antibody (INCA033989), Accepted for Presentation at EHA 2025

PR Newswire associated0

Skyhawk Therapeutics Has Advanced to the Multiple Ascending Dose Portion of its Phase 1 Study evaluating SKY-0515, a RNA-Targeting Small Molecule for Huntington's Disease